Anaheim, CA, Oct. 12, 2017 (GLOBE NEWSWIRE) -- LiveWire Ergogenics, Inc. (OTC PINK: LVVV), a company focused on research partnerships, product development and commercialization of cannabinoid-based products, today announced that it has further expanded its activities in the multi-billion dollar medical marijuana industry following an acquisition of a 3,000 square-foot, fully equipped Greenhouse.
“The purchase of this state of the art, fully climate-controlled Greenhouse is an important asset and a key element of our business strategy to capture significant market share in this rapidly expanding industry. It provides an important operational synergy with our current team of horticulturists and geneticists, as previously announced,” stated Bill Hodson, CEO of LiveWire Ergogenics. “The company is confident of a profitable operation based on the growing demand and increasingly favorable legal environment for cannabis in California and our proximity to cannabis-friendly Southern California regions.”
“This first LiveWire Greenhouse will provide our horticulture experts a turnkey nursery facility to produce high quality, pesticide-free and clean genetic clones. The nursery is designed to produce over 75,000 medicinal-strain clones per month that will generate significant revenue for the operation. LiveWire will provide crucial management and consulting services to the operation, as well as oversee the track and trace program,” concluded Hodson.
LiveWire’s strategy includes acquiring and leasing turnkey properties, selling location specific compliance packages and offering financing solutions for select candidates in the cannabis industry. The LiveWire management team will guide our experts into a legal, profitable and sustainable business by crafting business plans, design revenue models and provide compliance notifications. LiveWire does not grow, harvest or distribute marijuana that violates any local, state or federal laws.
About LiveWire Ergogenics, Inc.
LiveWire Ergogenics, Inc. (LVVV) is focused on identifying and monetizing current and future trends in the health and wellness industry. The Company is focused on establishing research partnerships to explore the application of cannabinoid-based products to target specific ailments or conditions with a large “sufferer” population for human and veterinarian applications. This includes the cloning of cannabis strains to produce positive medicinal results, dosing verification of zero pesticide products for quality brands and development and licensing of high-quality cannabinoid based products and services. The team at LiveWire Ergogenics has a passion for research and is committed to generate and implement innovative ideas and produce high-quality products that satisfy an increasing demand in this fast-growing industry.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, financial projections, statements regarding the plans and objectives of management for future operations, the development, regulatory approvals and commercialization of the Company’s products, or any of the Company’s other proposed products, systems or services.
Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and actual events may differ considerably. Factors that may cause actual results to differ materially from any projections may include, without limitation, the Company’s inability to obtain additional financing, delays in the development of its products, the impact of significant government regulation in the cannabis industry, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.